Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption

European Urology

Volumn 53, Issue 1, 2008, Pages 153-159

  Silva, João ^a,b   Silva, Carlos ^a,b,c   Saraiva, Luis ^a,b   Silva, André ^a,b   Pinto, Rui ^a   Dinis, Paulo ^a,b,c   Cruz, Francisco ^a,b,c  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Benign prostatic enlargement; Botulinum toxin; Prostate; Urinary retention

Indexed keywords

BOTULINUM TOXIN A; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ELDERLY CARE; HIGH RISK PATIENT; HUMAN; INDWELLING CATHETER; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION;

AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DISEASE PROGRESSION; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; NEUROMUSCULAR AGENTS; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY RETENTION; URINATION;

EID: 36448952295     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.050     Document Type: Article

References (29)

1. Dong M., Yeh F., Tepp W.H., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
2. Patel A.K., Patterson J.M., and Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50 (2006) 684-710
3. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
4. Doggweiler R., Zermann D.H., Ishigooka M., and Schmidt R.A. Botox-induced prostatic involution. Prostate 37 (1998) 44-50
5. Chuang Y.C., Huang C.C., Kang H.Y., et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 175 (2006) 1158-1163
6. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., and Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 (2003) 259-264
7. Kuo H.C. Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65 (2005) 670-674
8. Chuang Y.C., Chiang P.H., Huang C.C., Yoshimura N., and Chancellor M.B. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66 (2005) 775-779
9. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 1 Suppl. (1991) 4-8
10. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
11. Matani Y., Mottrie A.M., Stöckle M., Voges G.E., Fichtner J., and Hohenfellner R. Transurethral prostatectomy: a long-term follow-up study of 166 patients over 80 years of age. Eur Urol 30 (1996) 414-417
12. Hamel M.B., Henderson W.G., Khuri S.F., and Daley J. Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery. J Am Geriatr Soc 53 (2005) 424-429
13. Grise P., Plante M., Palmer J., et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46 (2004) 496-502
14. Rapp D.E., Turk K.W., Bales G.T., and Cook S.P. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol 175 (2006) 1138-1142
15. Duggan M.J., Quinn C.P., Chaddock J.A., et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277 (2002) 34846-34852
16. Morenilla-Palao C., Planells-Cases R., Garcia-Sanz N., and Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279 (2004) 25665-25672
17. Dinis P., Charrua A., Avelino A., et al. The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 48 (2005) 162-167
18. Ruggieri M.R., Colton M.D., Wang P., et al. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther 274 (1995) 976-982
19. Epstein J.I. The prostate and seminal vesicles. In: Sternberg S.S. (Ed). Diagnostic surgical pathology (1989), Raven, New York 1393-1432
20. Shapiro E., Becich M.J., Hartanto V., and Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147 (1992) 1293-1297
21. MacKenzie I., Burnstock G., and Dolly J.O. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7 (1982) 997-1006
22. Chon J.K., Borkowski A., Partin A.W., Isaacs J.T., Jacobs S.C., and Kyprianou N. Alpha1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161 (1999) 2002-2008
23. Marinese D., Patel R., and Walden P.D. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54 (2003) 230-237
24. Lin A.T.L., Yang A.H., and Chen K.-K. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 52 (2007) 582-589
25. Nasu K., Moriyama N., Kawabe K., et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119 (1996) 797-803
26. van der A.A.F., Roskams T., Blyweert W., Ost D., Bogaert G., and De Ridder D. Identification of kit positive cells in the human urinary tract. J Urol 171 (2004) 2492-2496
27. Exintaris B., Nguyen D.T., Dey A., and Lang R.J. Spontaneous electrical activity in the prostate gland. Auton Neurosci 126-127 (2006) 371-379
28. Reitz A., Stöhrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
29. Haferkamp A., Schurch B., Reitz A., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46 (2004) 784-791